Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Nyholm
Dag
D
Department of Neuroscience, Neurology, Uppsala University Hospital, SE-751 85 Uppsala, Sweden. dag.nyholm@neurologi.uu.se
Jansson
Rasmus
R
Willows
Thomas
T
Remahl
Ingela Nilsson
IN
D000405:Akinetic Mutism / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects; D021081:Chronobiology Disorders / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D015259:Dopamine Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004361:Drug Tolerance / Q000502:physiology; D004386:Duodenum / Q000502:physiology; D006801:Humans; D007260:Infusion Pumps; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology*; D012189:Retrospective Studies; D012893:Sleep Wake Disorders / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D013995:Time; D013997:Time Factors; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D007980:Levodopa